Table 5.
Univariate Cox regression analyses of OS and PFS in 126 enrolled pRCC patients from FUSCC cohort.
| OS |
PFS |
|||
|---|---|---|---|---|
| Covariates | HR (95%CI) | p-value | HR (95%CI) | p-value |
| Age at surgery | 1.02 (1.00, 1.05) | .08 | 1.02 (1.00, 1.04) | .17 |
| BMI (kg/m2) | 0.83 (0.75, 0.92) | <.01 | 0.87 (0.79, 0.95) | <.01 |
| Tumour size (cm) | 1.17 (1.07, 1.29) | <.01 | 1.17 (1.08, 1.28) | <.01 |
| Laterality (Ref. left) | 0.75 (0.41, 1.35) | .33 | 0.97 (0.55, 1.73) | .92 |
| T stage (T1-T2) | 1.88 (1.02, 3.45) | .04 | 1.90 (1.05, 3.43) | .03 |
| N stage (Ref. N0) | 5.37 (2.91, 9.91) | <.01 | 5.75 (3.18, 10.40) | <.01 |
| M stage (Ref. M0) | 14.21 (7.24, 27.86) | <.01 | 14.36 (7.50, 27.47) | <.01 |
| AJCC stage | 7.52 (3.67, 15.43) | <.01 | 6.30 (3.25, 12.23) | <.01 |
| Furhman grade (Ref. 1–2) | 1.43 (0.64, 3.20) | .34 | 1.23 (0.59, 2.54) | .58 |
| PTTG1 expression (Ref. Low) | 2.90 (1.52, 5.55) | <.01 | 2.46 (1.35, 4.51) | <.01 |
PFS: progression-free survival; pRCC: papillary renal cell carcinoma; FUSCC: Fudan University Shanghai Cancer Centre; HR: hazard ratio; CI: confidence interval; BMI: body mass index; *p-value less than .05 was considered as statistically significant and marked in bold.